A full 14 years after founding CRO Clinipace, its longstanding CEO and president Jeff Williams is planning to step down.

The TRK TKI achieved a median duration of response of 28.6 months, suggesting its effect may last longer than that of the incumbent.

Big Pharma-backed antifibrotic startup Blade has triggered the remaining tranche of last summer’s $45 million series B after placing its bets on a leading…

Johnson & Johnson had painted sirukumab and talacotuzumab as future blockbusters that would drive growth for years. Today, J&J abandoned those plans.

Drug accelerator Cydan has gained a $34 million injection as it eyes deeper inroads into rare diseases for its second fund.

Sanofi veteran Christopher Winter has been appointed as the new chief of R&D at drug discovery biotech Silicon.

Atlas Venture, Lightstone Ventures and OrbiMed put up the cash to equip Gemini to turn advances in our understanding of AMD genetics into a pipeline.

The MET-TKI triggered partial responses in a significant minority of NSCLC patients who had progressed after treatment with an EGFR-TKI.

AstraZeneca admitted that some early data for Acerta's BTK inhibitor acalabrutinib was crooked.

The ALK inhibitor triggered responses in a significant minority of heavily pretreated patients, suggesting it can play a role in NSCLC treatment.